Brought to you by 
Dainippon options rights to SanBio's stroke candidate SB623; exercised; terminated
16 Dec 2019
Executive Summary
SanBio Inc. (neural stem cell medicines) has given Dainippon Sumitomo Pharma Co. Ltd., the drug and food products division of Sumitomo Chemical Co., an option to license exclusive US and Canadian development and marketing rights to its lead candidate SB623, which is undergoing preclinical tests for disabilities caused by stroke.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dainippon options rights to SanBio's stroke candidate SB623; exercised; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice